HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability.

AbstractOBJECTIVE:
ADP is a key platelet agonist in thromboembolism. One of the receptors involved in ADP-induced platelet activation is the P2Y12 receptor, which is a target for antithrombotic drugs.
METHODS AND RESULTS:
Here, we present first evidence for a differential role of this receptor in thrombus and embolus formation in vivo. Anesthetized rabbits were treated with the selective P2Y12 antagonists AR-C69931 MX (3 microg x kg x min(-1) IV) or clopidogrel (25 mg/kg orally). Efficacy of these treatments was monitored by aggregation and thrombin generation measurements in blood samples ex vivo. Mesenteric arterioles were mechanically injured; thrombus growth and subsequent embolus formation were visualized by real-time intravital microscopy. AR-C69931 MX and clopidogrel significantly (P<0.05) reduced the total duration of embolization (by 52% and 36%, respectively), and fewer and smaller emboli were produced. The size of the initial thrombus was significantly reduced (P<0.005), but its stability was unaffected: plug formation was still effective.
CONCLUSIONS:
These findings demonstrate that ADP and its P2Y12 receptor are involved in thrombus growth and especially in the formation of emboli on the downstream side of the initial thrombus. This may explain the beneficial effects of P2Y12 receptor antagonists in secondary prevention of ischemic events in patients with arterial thrombosis.
AuthorsMiriam A van Gestel, Johan W M Heemskerk, Dick W Slaaf, Viviane V T Heijnen, Robert S Reneman, Mirjam G A oude Egbrink
JournalArteriosclerosis, thrombosis, and vascular biology (Arterioscler Thromb Vasc Biol) Vol. 23 Issue 3 Pg. 518-23 (Mar 01 2003) ISSN: 1524-4636 [Electronic] United States
PMID12615691 (Publication Type: Journal Article)
Chemical References
  • Membrane Proteins
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2Y12
  • Adenosine Monophosphate
  • cangrelor
  • Clopidogrel
  • Thrombin
  • Ticlopidine
  • Calcium
Topics
  • Adenosine Monophosphate (analogs & derivatives, pharmacology)
  • Administration, Oral
  • Animals
  • Blood Platelets (metabolism)
  • Calcium (metabolism)
  • Clopidogrel
  • Female
  • Male
  • Membrane Proteins
  • Platelet Activation (drug effects)
  • Platelet Aggregation (drug effects)
  • Purinergic P2 Receptor Antagonists
  • Rabbits
  • Receptors, Purinergic P2Y12
  • Thrombin (biosynthesis)
  • Thromboembolism (drug therapy, metabolism)
  • Ticlopidine (analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: